|
Jul 31
|
GSK Becomes Latest Pharma Firm To Lift Outlook
|
|
Jul 31
|
ViiV Healthcare announces positive data demonstrating 2-drug regimen DOVATO is as effective as 3-drug regimen BIKTARVY for maintenance therapy of HIV-1
|
|
Jul 31
|
Microsoft’s Pain Is Nvidia’s Gain. Why Chip Makers Are the Big AI Winners.
|
|
Jul 30
|
Nvidia slumps as Big Tech sell-off deepens
|
|
Jul 30
|
Pfizer Posts First Quarterly Revenue Growth Since Peak COVID Vaccine Sales
|
|
Jul 30
|
These Stocks Are Moving the Most Today: Merck, CrowdStrike, Microsoft, Nvidia, P&G, PayPal, Pfizer, Corning, JetBlue, Howmet, and More
|
|
Jul 30
|
S&P 500, Nasdaq Dive As Microsoft Earnings Loom; Two Dow Jones Leaders Crater On Earnings (Live Coverage)
|
|
Jul 30
|
Pfizer Raises Outlook Amid Strong Demand for Non-Covid Products
|
|
Jul 30
|
Top Midday Stories: June US Job Openings Drop; Merck Cuts 2024 Non-GAAP EPS Forecast; Pfizer Adjusted Earnings Fall; Procter & Gamble Net Sales Decline; S&P Global Reports Higher Results, Lifts Fiscal 2024 Outlook; BP Underlying Earnings Gain; Meta Pla...
|
|
Jul 30
|
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
|
|
Jul 30
|
Why this analyst is 'extremely bullish' on biopharma
|
|
Jul 30
|
Heard on the Street: Pfizer Finally Gets Past Covid
|
|
Jul 30
|
Stock Market Today: Stock Market News And Analysis
|
|
Jul 30
|
Pfizer Stock, In A Buy Zone, Sinks Despite Strong Earnings, Guidance Boost
|
|
Jul 30
|
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
|
|
Jul 30
|
Q2 earnings: Has Pfizer bucked declining COVID business?
|
|
Jul 30
|
Drugmaker Pfizer hikes 2024 forecast again after initially underwhelming Wall Street
|
|
Jul 30
|
Pfizer Raises Full-Year Outlook Following Second-Quarter Beat
|
|
Jul 30
|
Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings
|
|
Jul 30
|
Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
|